Table 1.
Baseline Characteristics of Study Population
|
Total n = 9438 |
Onset‐to‐sample collection time | P value | |||
|---|---|---|---|---|---|
|
<24 h n = 1942 |
24–72 h n = 3953 |
72 h–8 d n = 3543 |
|||
| Age, y | 63 (54–70) | 63 (55–71) | 63 (54–71) | 62 (54–69) | <0.001 |
| Male | 6732 (68.48) | 1315 (67.71) | 2681 (67.82) | 2455 (69.29) | 0.19 |
| Body mass index, kg/m2 | 24.49 (22.58–26.57) | 24.47 (22.49–26.42) | 24.47 (22.50–26.56) | 24.49 (22.66–26.67) | 0.21 |
| Current smoking | 2954 (31.30) | 613 (31.57) | 1211 (30.63) | 1194 (32.32) | 0.20 |
| Medical history | |||||
| Stroke | 2149 (22.77) | 470 (24.20) | 905 (22.89) | 774 (21.85) | 0.13 |
| Hypertension | 5955 (63.10) | 1171 (60.33) | 2523 (63.82) | 2261 (63.82) | 0.03 |
| Diabetes | 2262 (23.97) | 436 (22.45) | 945 (23.91) | 881 (24.87) | 0.13 |
| Dyslipidemia | 814 (8.62) | 159 (8.19) | 336 (8.50) | 319 (9.00) | 0.55 |
| Coronary artery disease | 1082 (11.01) | 255 (13.13) | 425 (10.75) | 347 (9.79) | <0.001 |
| Atrial fibrillation | 694 (7.35) | 197 (10.14) | 267 (6.75) | 230 (6.49) | <0.001 |
| NIHSS at admission | <0.001 | ||||
| ≤3 | 5000 (52.98) | 974 (50.15) | 2064 (52.21) | 1962 (55.38) | |
| 3–10 | 3702 (39.22) | 772 (39.75) | 1581 (39.99) | 1349 (38.08) | |
| >10 | 736 (7.80) | 196 (10.09) | 308 (7.79) | 232 (6.55) | |
| Prestroke mRS score 2–5 | 814 (8.62) | 185 (9.53) | 341 (8.63) | 288 (8.13) | 0.35 |
| Index event | <0.001 | ||||
| TIA | 667 (7.07) | 184 (9.47) | 301 (7.61) | 182 (5.14) | |
| Ischemic stroke | 8771 (92.93) | 1758 (90.53) | 3652 (92.39) | 3361 (94.86) | |
| rt‐PA treatment | 966 (10.24) | 444 (22.86) | 330 (8.35) | 192 (5.42) | <0.001 |
| Baseline leukocyte count, 109/L | 5.71 (8.41–4.01) | 7.15 (5.81–8.74) | 6.84 (5.67–8.40) | 6.89 (5.70–8.25) | <0.001 |
| LDL, mmol/L | 2.32 (1.73–2.98) | 2.44 (1.81–3.15) | 2.43 (1.85–3.10) | 2.11 (1.61–2.73) | <0.001 |
| Medication during hospitalization | |||||
| Antiplatelet | 9105 (96.94) | 1863 (96.38) | 3822 (97.13) | 3420 (97.05) | 0.26 |
| Anticoagulants | 962 (10.24) | 235 (12.16) | 384 (9.76) | 343 (9.73) | 0.005 |
| Antihypertensive | 4429 (47.16) | 853 (44.13) | 1857 (47.19) | 1719 (48.78) | 0.007 |
| Antidiabetic | 2430 (25.87) | 454 (23.49) | 1003 (25.49) | 973 (27.61) | 0.003 |
| Statin | 9099 (99.76) | 1865 (99.79) | 3821 (99.74) | 3413 (99.77) | 0.94 |
| hsCRP, mg/L | 1.77 (0.82–4.71) | 2.01 (0.89–5.02) | 1.72 (0.82–4.60) | 1.72 (0.80–4.63) | 0.002 |
| TOAST classification | <0.001 | ||||
| Large‐artery atherosclerosis | 2336 (24.75) | 481 (24.77) | 942 (23.83) | 913 (25.77) | |
| Cardioembolism | 633 (6.71) | 171 (8.81) | 263 (6.65) | 199 (5.62) | |
| Small‐artery occlusion | 1985 (21.03) | 369 (19.00) | 890 (22.51) | 726 (20.49) | |
| Other determined etiology | 106 (1.12) | 22 (1.13) | 43 (1.09) | 41 (1.16) | |
| Undetermined etiology | 4378 (46.39) | 899 (46.29) | 1815 (45.91) | 1664 (46.97) | |
| Days from onset to recurrence | 37 (3–145) | 16 (2–115) | 48 (3–157) | 48 (6–153) | <0.001 |
| 1‐y stroke recurrence | 931 (9.86) | 221 (11.38) | 367 (9.28) | 343 (9.68) | 0.04 |
Variables are presented as median (interquartile range) or number (%).
hsCRP indicates high‐sensitivity C‐reactive protein; LDL, Low‐density lipoprotein cholesterol; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; rt‐PA, recombinant tissue plasminogen activator; TIA, transient ischemic attack; and TOAST, Trial of Org 10 172 in Acute Stroke Treatment.